Enanta Pharmaceuticals Inc (ENTA) - Total Liabilities

Latest as of June 2026: $195.80 Million USD

Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) has total liabilities worth $195.80 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Enanta Pharmaceuticals Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.

Enanta Pharmaceuticals Inc - Total Liabilities Trend (2011–2025)

This chart illustrates how Enanta Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Enanta Pharmaceuticals Inc asset portfolio.

Enanta Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Enanta Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Xinxiang Tianli Energy Co. Ltd. A SHE:301152	China	CN¥1.37 Billion
Integrated Service Technology TWO:3289	Taiwan	NT$3.89 Billion
D-Link Corp TW:2332	Taiwan	NT$5.07 Billion
Tesco PLC LSE:TSCO	UK	GBX28.02 Billion
Oxiquim S.A SN:OXIQUIM	Chile	CL$118.48 Billion
Hellenic Exchanges - Athens Stock Exchange SA AT:EXAE	Greece	€494.17 Million
Jahwa Electron KO:033240	Korea	₩318.87 Billion
Nanjing Wondux Environmental Protection Technology Corp Ltd SHG:688178	China	CN¥1.20 Billion

Liability Composition Analysis (2011–2025)

This chart breaks down Enanta Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Enanta Pharmaceuticals Inc (ENTA) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.76	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.94	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.66	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Enanta Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Enanta Pharmaceuticals Inc (2011–2025)

The table below shows the annual total liabilities of Enanta Pharmaceuticals Inc from 2011 to 2025.

Year	Total Liabilities	Change
2025-09-30	$216.01 Million	-12.84%
2024-09-30	$247.84 Million	+0.94%
2023-09-30	$245.54 Million	+314.37%
2022-09-30	$59.26 Million	+43.02%
2021-09-30	$41.43 Million	+17.67%
2020-09-30	$35.21 Million	+28.80%
2019-09-30	$27.34 Million	+33.04%
2018-09-30	$20.55 Million	-17.68%
2017-09-30	$24.96 Million	+120.10%
2016-09-30	$11.34 Million	+15.07%
2015-09-30	$9.86 Million	+45.78%
2014-09-30	$6.76 Million	+3.94%
2013-09-30	$6.50 Million	-20.99%
2012-09-30	$8.23 Million	-94.79%
2011-09-30	$158.06 Million	--

About Enanta Pharmaceuticals Inc

NASDAQ:ENTA USA Biotechnology

Market Cap

$364.65 Million

Market Cap Rank

#13981 Global

#3349 in USA

Share Price

$12.52

Change (1 day)

-1.42%

52-Week Range

$7.17 - $16.85

All Time High

$126.37